The Combination of Cyproterone Acetate and Low Dose Diethylstilbestrol in the Treatment of Advanced Prostatic Carcinoma

Abstract

Cyproterone acetate is a steroidal antiandrogen with weak progestational activity that results in the partial suppression of pituitary gonadotropin. We demonstrate that the associated decrease in serum testosterone is more complete and prolonged if cyproterone acetate (200 mg. daily) is combined with a low dose of diethylstilbestrol (0.1 mg. daily). The effectiveness of the combination in the treatment of prostatic carcinoma was investigated in 51 patients with stage D2 malignancy. From an initial concentration of 360 +/- 23 ng. per dl. (mean +/- standard error), serum testosterone decreased to 56 +/- 5 ng. per dl. after 1 week and reached a plateau of approximately 30 ng. per dl. after 2 months. This was accompanied by a decrease in serum prostatic acid phosphatase from a mean starting concentration of 43 +/- 11 ng. per ml. to a low of 3 +/- 1 ng. per ml. at 12 months; the proportion of normal values increased from 10 to 80 per cent. A complete response was observed in 7 patients (13 per cent), partial response in 35 (69 per cent) and stable disease in 8 (16 per cent), yielding an over-all objective response rate of 98 per cent (1980 National Prostatic Cancer Project criteria). The actuarial median time to progression was 17 months and the median survival time was 23.5 months. In 26 patients who subsequently had signs of progressive carcinoma the relapse rate in bone (85 per cent) far exceeded that in nonskeletal sites (23 per cent). The incidence of cardiovascular toxicity was 12 per cent. These results indicate that cyproterone acetate and low dose diethylstilbestrol may be co-administered to achieve a synergistic and potent androgen withdrawal effect in the treatment of advanced prostatic carcinoma.

Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database

“…Research conducted under the auspices of the European Organization for Research and Treatment of Cancer (EORTC) and based on randomized controlled clinical trials has suggested that the cardiovascular toxicity associated with CPA is much lower than for diethylstilbestrol (DES), medroxyprogesterone acetate or estramustine phosphate [2–5]. The EORTC trial comparing CPA with flutamide revealed that the difference in VTE rates between the groups was not statistically significant (relative risk 2.32, 95% CI 0.61–8.80) [6].…”

A Simple Protocol to Stabilize Gold Nanoparticles using Amphiphilic Block Copolymers: Stability Studies and Viable Cellular Uptake

“…Death rates vary by extent of disease but remain continuous over time. Tumor cell sensitivities vary not only by the site of spread (with progression rare in soft tissue sites) but also once the disease has been established in bone and when the first progression occurs in bone 57. Thus, to improve overall outcomes, treatments are needed that will eliminate nonproliferating cells, prevent regrowth, or promote cell death.…”

Novel strategies and therapeutics for the treatment of prostate carcinoma

“…A frequent concern regarding the clinical application of biologic, immunologic, and genetic approaches 157 Also, the radionuclide bone scan is an imprecise tool for assessing osseous disease. It is an indirect measure of activity because there is no direct visualization of the tumor, there is a lag time between an antitumor effect and a change in the scan, interpretation can be confounded by the flare phenomenon, 158 and the criteria by which bone scans are deemed to have improved or worsened vary.…”